APA (7th ed.) Citation

Lu, S., Wu, L., Jian, H., Chen, Y., Wang, Q., Fang, J., . . . Zhang, C. (2022). Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): First interim results from a randomised, double-blind, multicentre, phase 3 trial. The lancet oncology, 23(9), 1167-1179. https://doi.org/10.1016/S1470-2045(22)00382-5

Chicago Style (17th ed.) Citation

Lu, Shun, et al. "Sintilimab Plus Bevacizumab Biosimilar IBI305 and Chemotherapy for Patients with EGFR-mutated Non-squamous Non-small-cell Lung Cancer Who Progressed on EGFR Tyrosine-kinase Inhibitor Therapy (ORIENT-31): First Interim Results from a Randomised, Double-blind, Multicentre, Phase 3 Trial." The Lancet Oncology 23, no. 9 (2022): 1167-1179. https://doi.org/10.1016/S1470-2045(22)00382-5.

MLA (9th ed.) Citation

Lu, Shun, et al. "Sintilimab Plus Bevacizumab Biosimilar IBI305 and Chemotherapy for Patients with EGFR-mutated Non-squamous Non-small-cell Lung Cancer Who Progressed on EGFR Tyrosine-kinase Inhibitor Therapy (ORIENT-31): First Interim Results from a Randomised, Double-blind, Multicentre, Phase 3 Trial." The Lancet Oncology, vol. 23, no. 9, 2022, pp. 1167-1179, https://doi.org/10.1016/S1470-2045(22)00382-5.